Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferons in dermatology.

R Stadler1, A Mayer-da-Silva, B Bratzke

  • 1Department of Dermatology, University Medical Center Steglitz, Freie Universität Berlin, F.R. Germany.

Journal of the American Academy of Dermatology
|April 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characteristics and quality of life of nine-year survivors with metastatic melanoma treated with pembrolizumab beyond second-line therapy.

European journal of cancer (Oxford, England : 1990)·2025
Same author

Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Early switch from run-in with targeted to immunotherapy in advanced BRAF<sup>V600</sup>-positive melanoma: final results of the randomised phase II ImmunoCobiVem trial.

ESMO open·2025
Same author

Survival of European children, adolescents and young adults diagnosed with haematological malignancies in the period 2000-2013: Results from EUROCARE-6, a population-based study.

European journal of cancer (Oxford, England : 1990)·2025
Same author

Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

An update on access to novel treatment for metastatic melanoma in Europe - A 2024 survey of the European melanoma registry and the European association of dermato-oncology.

European journal of cancer (Oxford, England : 1990)·2024

Interferons, proteins with antiviral and antitumoral effects, show promise in treating conditions like Kaposi's sarcoma and Behçet's disease. While single-agent use in melanoma has limited success, combination therapy may improve outcomes.

Area of Science:

  • Immunology and Biotechnology
  • Protein Therapeutics
  • Cellular Metabolism

Background:

  • Interferons are proteins and glycoproteins with diverse biological activities.
  • These activities include antiviral, antiproliferative, antitumoral, and immunomodulatory effects.
  • Their functions are mediated by binding to specific cell membrane receptors, altering cellular metabolism.

Purpose of the Study:

  • To review the therapeutic applications of interferons in various medical conditions.
  • To evaluate the efficacy of recombinant interferon-alpha-2a in specific patient cohorts.
  • To assess the role of interferons as a single agent versus combination therapy.

Main Methods:

  • Review of clinical trials and therapeutic regimens involving interferons.

Related Experiment Videos

  • Clinical experience with long-term, high-dose subcutaneous recombinant interferon-alpha-2a.
  • Analysis of treatment outcomes for viral papillomas, HIV-associated Kaposi's sarcoma, cutaneous tumors, and inflammatory dermatoses.

    • Main Results:

    • Long-term interferon-alpha-2a therapy achieved remission or stabilization in HIV-associated Kaposi's sarcoma.
    • Interferon monotherapy showed a low response rate in metastatic malignant melanoma.
    • Interferon demonstrated effectiveness in treating Behçet's disease and condylomata acuminata, and potential as a combination agent in melanoma.

    Conclusions:

    • Recombinant interferon-alpha-2a can be effective for specific conditions like Kaposi's sarcoma and Behçet's disease.
    • Interferon's utility in malignant melanoma may be enhanced when used in combination with other antitumor agents.
    • Further research and varied regimens are needed to fully elucidate interferon's therapeutic potential.